Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex.
Article Details
- CitationCopy to clipboard
Kam GY, Leung KC, Baxter RC, Ho KK
Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex.
J Clin Endocrinol Metab. 2000 May;85(5):1918-22.
- PubMed ID
- 10843175 [ View in PubMed]
- Abstract
We have previously shown that exogenous estrogens exert route-dependent effects on serum GH and insulin-like growth factor I (IGF-I) levels. IGF-I circulates as a ternary complex with IGF-binding protein-3 (IGFBP-3) and the acid-labile subunit (ALS). It is not known whether IGFBP-3 and ALS in blood are regulated by estrogen and, if so, whether this is also route dependent. In the present study we investigate the effects on IGFBP-3 and ALS of oral and transdermal estrogens (study 1), of different oral estrogen formulations (ethinyl estradiol, conjugated estrogen, and estradiol valerate; study 2), of different estrogen dosages (study 3) in normal postmenopausal women, and of oral estrogen in hypogonadal GH-deficient women (study 4). Administration of oral, but not transdermal, estrogen in normal postmenopausal women significantly decreased serum levels of IGFBP-3 and ALS (P < or = 0.005). The suppressive effects were similar with different oral estrogen formulations, and the degree of suppression increased with estrogen dosage. In hypogonadal GH-deficient women, oral estrogen treatment also significantly reduced IGFBP-3 and ALS (P = 0.02). The changes in IGF-I in each of the four studies paralleled the changes in both IGFBP-3 and ALS. In conclusion, exogenous estrogens suppress serum IGFBP-3 and ALS in a route- and dose-dependent manner, which are in parallel with the effects on serum IGF-I. These actions of oral estrogen are independent of endogenous GH status.
DrugBank Data that Cites this Article
- Pharmaco-proteomics
Drug Drug Groups Gene Gene ID Change Interaction Chromosome Estradiol Approved Investigational Vet Approved FSHB 2488 decreased estradiol valerate results in decreased expression of FSHB protein 11p14.1 Estradiol Approved Investigational Vet Approved IGF1 3479 decreased estradiol valerate results in decreased expression of IGF1 protein 12q23.2 Estradiol Approved Investigational Vet Approved IGFALS 3483 decreased estradiol valerate results in decreased expression of IGFALS protein 16p13.3 Estradiol Approved Investigational Vet Approved IGFBP3 3486 decreased estradiol valerate results in decreased expression of IGFBP3 protein 7p12.3 Estradiol Approved Investigational Vet Approved LHB 3972 decreased estradiol valerate results in decreased expression of LHB protein 19q13.3 Ethinylestradiol Approved IGFALS 3483 decreased Ethinyl Estradiol results in decreased expression of IGFALS protein 16p13.3 Ethinylestradiol Approved IGFBP3 3486 decreased Ethinyl Estradiol results in decreased expression of IGFBP3 protein 7p12.3 Estradiol Approved Investigational Vet Approved GH1 2688 increased estradiol valerate results in increased expression of GH1 protein 17q23.3 Ethinylestradiol Approved GH1 2688 increased Ethinyl Estradiol results in increased expression of GH1 protein 17q23.3 Ethinylestradiol Approved LHB 3972 decreased Ethinyl Estradiol results in decreased expression of LHB protein 19q13.3 Ethinylestradiol Approved LHB 3972 decreased Ethinyl Estradiol results in decreased expression of LHB protein 19q13.3 Ethinylestradiol Approved FSHB 2488 decreased Ethinyl Estradiol results in decreased expression of FSHB protein 11p14.1 Ethinylestradiol Approved FSHB 2488 decreased Ethinyl Estradiol results in decreased expression of FSHB protein 11p14.1 Ethinylestradiol Approved FSHB 2488 decreased Ethinyl Estradiol results in decreased expression of FSHB protein 11p14.1 Ethinylestradiol Approved IGF1 3479 decreased Ethinyl Estradiol results in decreased expression of IGF1 protein 12q23.2 Ethinylestradiol Approved IGF1 3479 decreased Ethinyl Estradiol results in decreased expression of IGF1 protein 12q23.2